No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma

byKathleen Lau

March 4, 2021

in StudyGraphics

RELATED REPORTS

FDA grants priority review for iberdomide-based myeloma regimen

Replacing sedentary time with physical activity may lower risk of all-cause mortality

2 Minute Medicine: Pharma Roundup – Merck and Mayo Clinic’s AI precision medicine lab, Novartis’ remibrutinib hits Phase III hive endpoint, FDA grants priority review for iberdomide in myeloma, oral infigratinib boosts growth velocity in achondroplasia, and shingles vaccine/sildenafil linked to lower Alzheimer’s risk [February 2026]

#VisualAbstract: Higher metastatic lymph node burden is associated with worse overall survival in Merkel cell carcinoma

RelatedReports

Variation noted across pre- and post-marketing studies for FDA approved devices

Hematology

FDA grants priority review for iberdomide-based myeloma regimen

March 6, 2026

Reduced gestational weight gain with lifestyle intervention

Cardiology

Replacing sedentary time with physical activity may lower risk of all-cause mortality

March 2, 2026

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Chronic Disease

2 Minute Medicine: Pharma Roundup – Merck and Mayo Clinic’s AI precision medicine lab, Novartis’ remibrutinib hits Phase III hive endpoint, FDA grants priority review for iberdomide in myeloma, oral infigratinib boosts growth velocity in achondroplasia, and shingles vaccine/sildenafil linked to lower Alzheimer’s risk [February 2026]

February 26, 2026

AI Roundup

Artificial intelligence predicts colorectal cancer in ulcerative colitis with 99% accuracy

February 20, 2026

Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]

Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma

#VisualAbstract: Cemiplimab monotherapy significantly improves outcomes in patients with advanced non-small-cell lung cancer with PD-L1 of at least 50%

#VisualAbstract: Relugolix combination therapy led to reduction in uterine fibroid symptoms

#VisualAbstract OAsIS: Ibrutinib, obinutuzumab, and venetoclax was well-tolerated and showed high response rates in both untreated and relapsed mantle cell lymphoma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result